Results 1 to 10 of about 2,144 (203)

Case Report: Omadacycline in the Treatment of Community-Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies. [PDF]

Clin Case Rep
Omadacycline, a novel once‐daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community‐acquired pneumonia (CAP) in adults.
Xu Z, Pan W, Lei H, Dong C, Zou B, Shu S, Zhang W.   +6 more
europepmc   +3 more sources

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database. [PDF]

Front Pharmacol
ObjectiveOmadacycline is a newly launched drug of tetracycline. Therefore, it is necessary to comprehensive evaluate reports on the safety of omadacycline in large, real-world populations.
Shi X, Wang C, Liu X, Zou L, Guo P.
europepmc   +5 more sources

Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial. [PDF]

EClinicalMedicine
Summary: Background: Omadacycline is a first-in-class aminomethylcycline antibiotic approved to treat adults with community-acquired bacterial pneumonia (CABP).
File TM, Kaye KS, Ihor S, Hovbakh I, Katsarava V, Kirsch C, Soni K, Gupta K, Manley A, Deck DH, Anastasiou D, Chitra S, Villano S.   +12 more
europepmc   +2 more sources

Efficacy and safety of omadacycline for the treatment of infectious diseases: a real-world, retrospective study of 2587 patients. [PDF]

Front Pharmacol
ObjectivePrevious randomized controlled trials have shown good efficacy and safety of omadacycline in patients with infectious diseases, but relevant real-world evidence is still insufficient.
Liu J, Liu J, Li H, Pang J, Chen S, Liu J, Ouyang A.   +6 more
europepmc   +2 more sources

Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance. [PDF]

Drugs R D
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative ...
Sun H, Hou X, Zhu Q, Liu J, Zhai Q, Shi K.   +5 more
europepmc   +2 more sources

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. [PDF]

BMC Infect Dis
Background Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary.
Kong WQ, Shu YF, Tang J, Li SQ, Zhong H, Zhang XY.   +5 more
europepmc   +2 more sources

A matched pilot cohort study of intravenous omadacycline in the treatment of severe pneumonia associated with carbapenem-resistant <i>Acinetobacter baumannii</i>. [PDF]

Front Microbiol
BackgroundCarbapenem-resistant Acinetobacter baumannii (CRAB)-caused severe pneumonia is associated with high mortality rates, and treatment options are limited.
Chen D, Chen Y, Hu N, Gu Q, Kan J, Liu J, Zhang H.   +6 more
europepmc   +2 more sources

Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards ...
Michael D Huband, Dee Shortridge
exaly   +3 more sources

In vitro activity and in vivo efficacy of omadacycline against Plasmodium species. [PDF]

Malar J
Background Doxycycline is currently the only tetracycline-class antibiotic recommended for malaria prophylaxis. Omadacycline, a semisynthetic aminomethylcycline approved for treatment of adults with community-acquired bacterial pneumonia and acute ...
Madejczyk MS, Leed SE, Kudyba K, Roth A, Martin ML, Lee P, Anastasiou D, Pierce JV, Serio AW, Caridha D.   +9 more
europepmc   +2 more sources

LC-MS/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application. [PDF]

Sci Rep
Omadacycline, a third-generation tetracycline antibiotic, exhibits time-dependent pharmacokinetics. The ratio of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC0−24/MIC) serves as the primary pharmacokinetic ...
Wang Y, Diao Z, Qu Y, Fan K, Feng C, Lv B, Yu Y, Geng Z.   +7 more
europepmc   +2 more sources